导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 15.71% | 568/4773 |
| 近一周 | -0.28% | 1015/5465 |
| 近一月 | 5.99% | 43/5421 |
| 近一季 | 6.77% | 249/5231 |
| 近半年 | 18.76% | 250/4920 |
| 近一年 | 22.86% | 395/4394 |
| 近两年 | 82.40% | 814/2954 |
| 近三年 | 106.67% | 133/2253 |
| 成立以来 | 101.45% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.50% 1525/4961 |
-0.28% 3276/5312 |
- - |
- - |
| 2025 | 34.03% 1083/4813 |
11.67% 270/3635 |
11.21% 205/4076 |
-0.67% 3935/4524 |
8.65% 233/4813 |
| 2024 | 33.75% 66/3463 |
3.93% 496/2808 |
14.00% 15/3014 |
3.82% 2916/3129 |
8.73% 373/3463 |
| 2023 | 0.92% 384/2656 |
-0.53% 1799/2280 |
7.18% 34/2385 |
-5.93% 1397/2515 |
0.63% 136/2655 |
| 2022 | 5.41% 19/2207 |
9.03% 12/1919 |
0.33% 1560/2016 |
-11.71% 567/2113 |
9.15% 236/2208 |
| 2021 | 3.18% 621/1822 |
13.24% 11/1255 |
-3.97% 1255/1330 |
-4.91% 749/1466 |
-0.23% 1215/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 鹏华香港银行指数(LOF)C VS. 长安沪深300非周期A(740101) |